NS

Nanjappan Shanthi

Active Director Director DIN 10814769
DIN 10814769 First appointment Oct 2024 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Nanjappan Shanthi

Data last updated:

Nanjappan Shanthi is a Director at Tritan Pharma Private Limited (since 2024). The company operates in Paper.

DIN 10814769
Primary Designation Director
Industry Paper
First Appointment 21 Oct 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Tritan Pharma Private Limited U21000TZ2024PTC032752
Director21 Oct 20242024Active

Board colleagues of Nanjappan Shanthi

NameDINCompanyDesignation
Deepakkumar10814770Tritan Pharma Private LimitedDirector
Rangasamy Nanjappan11386157Tritan Pharma Private LimitedAdditional Director

Directorship timeline

Open interactive timeline →
Tritan Pharma Private Limited
Premium access

Shareholding and investment profile for Nanjappan Shanthi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nanjappan Shanthi

Nanjappan Shanthi currently holds 1 directorship: Tritan Pharma Private Limited (Director, since 21 Oct 2024).

Nanjappan Shanthi was first appointed on 21 Oct 2024 as Director at Tritan Pharma Private Limited.

The current boards of Nanjappan Shanthi's companies include Deepakkumar (Tritan Pharma Private Limited), Rangasamy Nanjappan (Tritan Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available